Leo Pharma’s Vice President, Thomas Kongstad Petersen agrees:
“Leo Pharma welcomes the government’s initiative in the form of a growth team for life sciences. We look forward to working in collaboration with the growth team in order to find the recipe for generating growth in Denmark through the pharmaceutical industry.”
Denmark ideal for clinical trials
Besides being a member of the government’s latest initiative, Thomas Kongstad Petersen is also managing the public-private service Next, which focuses – thus far, with great success - on bringing clinical research from the international pharmaceutical industry to Denmark.
Denmark hosts more clinical trials per capita than any other country in the world. It is easy to recruit eligible study participants, and a single point of entry facilitates the identification and contact with leading clinical centres of excellence at hospitals nationwide.
Hece, the Danish national health system registers the entire population “from embryo to grave”; a system that means Denmark is home to more than 500 bio banks and extensive medical records. Denmark is also one of the fastest countries to approve clinical trials and has the largest commercial drug development pipeline in Europe.
Invest in Danish life sciences
The life science industry in Denmark has developed into one of the strongest clusters in Europe. With excellent interplay between public and private partners and a unique test environment, Denmark turns clinical research into business.
For many years, Denmark has constituted an international health laboratory, attracting international businesses and researchers. Reasons include the presence of several different types of healthcare industries, a long-standing tradition for efficient public-private partnerships, plus a keen political focus on creating framework conditions conducive to research and business development in healthcare and welfare.